Výsledky vyhledávání

Heavily pretreated ovarian cancer patients treated by single-agent gemcitabine. A retrospective outcome comparison between platinum-sensitive and platinum-resistant patients

Autor: Tally Levy, Dan Grisaru, Joseph Brenner, Mona Boaz, Ilan G. Ron, Henry Hayat, Moshe Inbar, Abraham Golan, Joseph Menczer, Tamar Safra

Publikováno v: Acta Oncologica. 45:463-468

To assess activity and toxicity of gemcitabine treatment in heavily pretreated epithelial ovarian cancer (EOC) patients and compare the outcome between platinum-sensitive and platinum-resistant patients. We conducted a retrospective analysis of 43 wo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abfc81c71b0f2ab43158d036df8e64b0
https://doi.org/10.1080/02841860500509035

Zobrazit plný text záznamu

Experience with sunitinib treatment for metastatic renal cell carcinoma in a large cohort of Israeli patients: outcome and associated factors

Autor: Dana, Livne-Segev, Maya, Gottfried, Natalie, Maimon, Avivit, Peer, Avivit, Neumann, Henry, Hayat, Svetlana, Kovel, Avishay, Sella, Wilmosh, Mermershtain, Keren, Rouvinov, Ben, Boursi, Rony, Weitzen, Raanan, Berger, Daniel, Keizman

Publikováno v: The Israel Medical Association journal : IMAJ. 16(6)

The VEGFR/PDGFR inhibitor sunitinib was approved in Israel in 2008 for the treatment of metastatic renal cell carcinoma (mRCC), based on an international trial. However, the efficacy of sunitinib treatment in Israeli mRCC patients has not been previo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::cfc16e7b9f9ba3fc858bc8f94e6e6f51
https://pubmed.ncbi.nlm.nih.gov/25058995

Zobrazit plný text záznamu

Activity of cabazitaxel after docetaxel and abiraterone acetate therapy in patients with castration-resistant prostate cancer

Autor: Daniel Keizman, Avishay Sella, Avivit Peer, Henry Hayat, Stephen Jay Frank, Tal Sella, David Sharide, Ekaterina Hanovich, Raanan Berger, Eli Gez, Victoria Neiman, Eli Rosenbaum, Svetlana Kovel

Publikováno v: Clinical genitourinary cancer. 12(6)

Background Cabazitaxel and AA have been approved by the US Food and Drug Administration for use after docetaxel in mCRPC. Recently, CAB appeared to be active when given after AA. AA is capable of inducing AR splice variants that confer ligand-indepen

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aad1e247c619ac8ce828e8afde08a6b8
https://pubmed.ncbi.nlm.nih.gov/25066221

Zobrazit plný text záznamu

Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma

Autor: Avivit Peer, Natalie Maimon, Maya Gottfried, Michael A. Carducci, Ben Boursi, Hans J. Hammers, Victoria J. Sinibaldi, Roberto Pili, Mario A. Eisenberger, Svetlana Kovel, Avishay Sella, Maya Ish-Shalom, Daniel Keizman, Henry Hayat, Raanan Berger

Publikováno v: European journal of cancer (Oxford, England : 1990). 48(7)

Bisphosphonates are used to prevent skeletal events of bone metastases, and may exhibit antitumour effects. We aimed to evaluate whether bisphosphonates can bring a response rate (RR), progression free survival (PFS) and overall survival (OS) benefit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f8186de8b928be04ea225f8e6d85e28
https://pubmed.ncbi.nlm.nih.gov/22682018

Zobrazit plný text záznamu

Targeting pulmonary metastases of renal cell carcinoma by inhalation of interleukin-2

Autor: M. Ben-Shahar, R. Katsenelson, H. Biran, V. Mermershtein, Tamar Peretz, H. Nehushtan, Rony Weitzen, E. Gez, D. Loven, A. Neumann, N. Karminsky, D. Matcejevsky, Ofer Merimsky, Moshe Inbar, Henry Hayat, R. Rubinov

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology. 15(4)

Introduction: Pulmonary metastases of renal cell carcinoma (RCC) are associated with poor prognosis. Inhalation therapy with interleukin-2 (IL-2) is thus an appealing method for palliation. This multicenter study summarizes the national experience of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dbd2461f5236fef4eee576cf6e93701a
https://pubmed.ncbi.nlm.nih.gov/15033668

Zobrazit plný text záznamu

Combined systemic chronotherapy and hepatic artery infusion for the treatment of metastatic colorectal cancer confined to the liver

Autor: Mordechai Shimonov, Samario Chaitchik, Joseph Brener, Henry Hayat, Pinhas Schachter, Abraham Czerniak

Publikováno v: Chemotherapy. 51(2-3)

Background: The optimal treatment of patients with metastatic colorectal cancer is still a clinical challenge. We describe the use of combined hepatic arterial infusion (HAI) of irinotecan (CPT-11) in conjunction with systemic chronotherapy infusion

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::117bfcd91ff1bf04a6c56779545a7730
https://pubmed.ncbi.nlm.nih.gov/15886466

Zobrazit plný text záznamu

Potential impact of prior high-dose IL-2 on the outcomes of sunitinib (Su) treatment (tx) in patients (pts) with metastatic renal cell carcinoma (mRCC)

Autor: David Sarid, Daniel Kejzman, Keren Rouvinov, Maya Gottfried, Mario A. Eisenberger, Avivit Peer, Raanan Berger, Victoria Neiman, Eli Rosenbaum, Victoria J. Sinibaldi, Avishay Sella, Wilmosh Mermershtain, Henry Hayat, Eliahu Gez, Hans J. Hammers, Michael A. Carducci

Publikováno v: Journal of Clinical Oncology. 32:494-494

494 Background: Targeted txs are the tx of choice in most mRCC pts. However, HDIL2 which may produce durable responses in a small percentage of cases, is still an option in carefully selected pts. While the effect of prior HDIL2 on the outcome of tar

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ec5e0e29db127a0af52c7ffd5be25f43
https://doi.org/10.1200/jco.2014.32.4_suppl.494

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání